title: Prevalence and genotype characterization of human papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso.
abstract: BACKGROUND
  Approximately, 15-20 of 40 HPVs that infect the female genital tract confer a high-risk of invasive cancer, thus HPVs account for 95% of cervix cancers. The objectives of this study were to: (i) estimate the prevalence of HPV infection in women infected with HIV in Ouagadougou, (ii) identify potential carcinogenic HPV strains and (iii) determine whether existing HPV vaccines match the isolated strains.
  
  
  METHODS
  From May 2009 to April 2010, 250 HIV-infected women were included in this study. Each woman was screened for the presence of HPV and for HPV genotype using PCR/hybridization technique.
  
  
  RESULTS
  Of the 250 HIV-infected women, 59.6% were infected with at least one type of HPV. High-risk HPVs were identified with the following prevalence: HPV-18 (25.0%); HPV-50'S (25.5%); HPV-30'S (20.8%); HPV-16 (4.7%); HPV-45 (3.7%). Low-risk HPVs were represented by HPV-6 (5.7%) and HPV-11 (0.9%).
  
  
  CONCLUSIONS
  The issue of the study showed that the existing vaccines: Gardasil and Cervarix may be used in the country although they match only HPV-16, HPV-18, HPV-6 and HPV-11. Further investigations should be continued for the establishment of vaccine that matches all genotypes circulating in the country.
authors.affiliation: Centre de Recherche Biomoléculaire Pietro Annigoni, CERBA/LABIOGENE, Ouagadougou, Burkina Faso.
authors.forename: F W
authors.initials: FW
authors.lastname: Djigma
authors.forename: C
authors.initials: C
authors.lastname: Ouédraogo
authors.forename: D S
authors.initials: DS
authors.lastname: Karou
authors.forename: T
authors.initials: T
authors.lastname: Sagna
authors.forename: C
authors.initials: C
authors.lastname: Bisseye
authors.forename: M
authors.initials: M
authors.lastname: Zeba
authors.forename: D
authors.initials: D
authors.lastname: Ouermi
authors.forename: C
authors.initials: C
authors.lastname: Gnoula
authors.forename: V
authors.initials: V
authors.lastname: Pietra
authors.forename: N W
authors.initials: NW
authors.lastname: Ghilat-Avoid-Belem
authors.forename: K
authors.initials: K
authors.lastname: Sanogo
authors.forename: J
authors.initials: J
authors.lastname: Sempore
authors.forename: S
authors.initials: S
authors.lastname: Pignatelli
authors.forename: A M
authors.initials: AM
authors.lastname: Ferri
authors.forename: J-B
authors.initials: JB
authors.lastname: Nikiema
authors.forename: J
authors.initials: J
authors.lastname: Simpore
mesh_terms: D000328:Adult; D002050:Burkina Faso / Q000453:epidemiology; D016172:DNA Fingerprinting; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D016679:Genome, Viral; D006678:HIV; D015658:HIV Infections / Q000453:epidemiology / Q000235:genetics; D006679:HIV Seropositivity / Q000453:epidemiology / Q000235:genetics; D006801:Humans; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000517:prevention & control
chemical_list: D004279:DNA, Viral; D053918:Papillomavirus Vaccines